Abstract Details

Title Disparities in Healthcare Utilization between Hispanic and Non-Hispanic Seizure Patients in Southern Arizona

Topic Epilepsy

Presentation(s) P03 - (-)

Poster/Presentation
Number 119

Objective

Background BACKGROUND: Other studies have reported differences in healthcare utilization in seizure patients based on sociodemographic characteristics, such as insurance status and communication/language barriers. To better serve communities that are sociodemographically diverse, disparities in healthcare utilization among Hispanic and non-Hispanic patients must be elucidated.

Design/Methods DESIGN/METHODS: Longitudinal data from January 2005 to July 2008 were obtained from a southern Arizona border hospital. Patients were categorized in terms of their discharge ICD-9 diagnoses: those with seizures [345.0-345.9 (epilepsy); 094.89 (epilepsy, syphilis); 123.1 (epilepsy, cysticercosis); 123.9 (epilepsy, parasite); 333.2 (progressive familial epilepsy); 347.0 (epilepsy, sleep); 907.0 (epilepsy due to traumatic injury); 780.3 and 780.39 (convulsions), and 780.31-780.32 (febrile convulsions)] versus those without. Hispanic and non-Hispanic seizure groups were compared with no-seizure groups in terms of total charges, procedure codes reported, length of stay, insurance status, and location of care. All analyses were performed using IBM SPSS version 20.

Results RESULTS: Mean total charges per visit was significantly different between Hispanics ($3279.91) and non-Hispanics ($6846.40) in the seizure group (p < 0.001). However, this significant difference was found only among adults (age 18-64; Hispanic: $4054.08; versus non-Hispanic: $6947.04), but not among children or seniors. Insurance status, location of care, length of stay, and procedures per visit are being investigated to discover the source of this disparity.

Conclusions CONCLUSIONS: Significant differences in total charges were found among Hispanic and non-Hispanic seizure adult patients (18-64 age group). Factors that may explain the differences are currently being elucidated, and may help us better serve and understand border communities.

Authors/Disclosures
Yeeck Sim, MD (Center for NeuroScience) PRESENTER	No disclosure on file
Anatevka S. Ribeiro, MD	Dr. Ribeiro has nothing to disclose.
	No disclosure on file
Bruce A. Cree, MD, PhD, MAS, FAAN (UCSF, Multiple Sclerosis Center)	The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
Kendra Drake, MD, FAAN (Western Neuro)	Dr. Drake has nothing to disclose.
David M. Labiner, MD (University of Arizona Health Sciences)	The institution of Dr. Labiner has received research support from CDC.

��ɫ��

��ɫ��